We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
IDRA-21 is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most IDRA-21 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1995–2005.
Based on 5 studies
Confidence
LowBy outcome
The current evidence for IDRA-21 is insufficient to assign an evidence score, based on 5 indexed studies. A grey-market 'research chemical' sold online as a memory-enhancing nootropic — IDRA-21 is a benzothiadiazine AMPAKINE, a positive allosteric modulator of AMPA glutamate receptors that slows their desensitization and so enhances glutamatergic transmission. The CRITICAL fact is the absence of human evidence: there are NO human clinical trials of IDRA-21. Its entire evidence base is rodent and non-human-primate behavioural studies plus in-vitro electrophysiology — work in which it improved learning/memory tasks and was reported several-fold more potent than the prototype ampakine aniracetam. That is genuinely promising preclinical pharmacology, but it has never been tested in people for either benefit or safety, and AMPA potentiation carries a theoretical EXCITOTOXICITY / seizure risk with chronic or high-dose use. Layered on top is grey-market reality: material of unverified identity, purity and dose, taken with no medical supervision. It is NOT an approved medicine, NOT a dietary supplement, and there is no human use this library can recommend. Informational, harm-reduction entry only — the honest takeaway is that IDRA-21 is essentially unstudied in humans. Representative study: PMID 7644474.
Sarcosine
Mostly mechanism / observationalAn endogenous glycine derivative that inhibits the type-1 glycine transporter (GlyT-1), enhancing NMDA-receptor co-agonism. It is studied as a prescription-style PSYCHIATRIC ADJUNCT — with genuine add-on RCTs in schizophrenia (and smaller signals in OCD and depression) — not as a casual nootropic. Evidence is real but narrow and emerging.
Tianeptine
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide) — a benzothiadiazine AMPAKINE (positive allosteric modulator of AMPA glutamate receptors) studied ONLY preclinically, with NO human clinical trials and sold as a grey-market 'research chemical' nootropic
A grey-market 'research chemical' sold online as a memory-enhancing nootropic — IDRA-21 is a benzothiadiazine AMPAKINE, a positive allosteric modulator of AMPA glutamate receptors that slows their desensitization and so enhances glutamatergic transmission. The CRITICAL fact is the absence of human evidence: there are NO human clinical trials of IDRA-21. Its entire evidence base is rodent and non-human-primate behavioural studies plus in-vitro electrophysiology — work in which it improved learning/memory tasks and was reported several-fold more potent than the prototype ampakine aniracetam. That is genuinely promising preclinical pharmacology, but it has never been tested in people for either benefit or safety, and AMPA potentiation carries a theoretical EXCITOTOXICITY / seizure risk with chronic or high-dose use. Layered on top is grey-market reality: material of unverified identity, purity and dose, taken with no medical supervision. It is NOT an approved medicine, NOT a dietary supplement, and there is no human use this library can recommend. Informational, harm-reduction entry only — the honest takeaway is that IDRA-21 is essentially unstudied in humans.
IDRA-21 is a benzothiadiazine AMPAKINE (positive allosteric modulator of AMPA glutamate receptors) with a coherent but ENTIRELY PRECLINICAL evidence base — rodent and non-human-primate learning/memory studies plus in-vitro electrophysiology — and NO human clinical trials of any kind. In monkeys it reversed an alprazolam-induced learning deficit and was estimated ~10x more potent than aniracetam (Thompson 1995); in rats it enhanced water-maze performance (Uzunov 1995); in cultured neurons it facilitated AMPA-receptor function while, unlike cyclothiazide, appearing devoid of neurotoxicity at tested concentrations (Impagnatiello 1997; Longone 1998), and it sits within the generally-procognitive positive-AMPA-modulator class (Black 2005). None of this is human evidence: there is no demonstrated benefit or safety in people, AMPA potentiation carries a theoretical excitotoxicity/seizure risk at high or chronic doses, and the compound is sold grey-market of unverified identity, purity and dose. The dominant signal is therefore an ABSENCE of human data against a plausible mechanistic harm, so the score sits low.
IDRA-21 — chemically 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide — is a benzothiadiazine AMPAKINE: a positive allosteric modulator of AMPA-subtype glutamate receptors.
Rather than activating the receptor itself, it binds an allosteric site and slows the rapid desensitization of AMPA-gated ion channels, so that each pulse of glutamate produces a larger, longer current.
The net effect is enhanced fast excitatory (glutamatergic) transmission, the kind that underlies hippocampal long-term potentiation and, by extension, learning and memory.
IDRA-21 is a structural and pharmacological congener of the prototype ampakine aniracetam, and in head-to-head preclinical work it was reported to be several-fold more potent. The honest description of its evidence base is that it is ENTIRELY PRECLINICAL.
There are NO human clinical trials of IDRA-21 — no approved indication anywhere, no human efficacy data, and no human safety or pharmacovigilance data on the material people actually buy.
What exists is a coherent animal and in-vitro literature, mostly from the 1990s: in patas monkeys, oral IDRA-21 reversed an alprazolam-induced learning deficit and was estimated roughly ten-fold more potent than aniracetam (Thompson 1995); in rats, racemic IDRA-21 enhanced water-maze performance, with activity residing in the (+)-enantiomer (Uzunov 1995); and in cultured neurons it facilitated AMPA-receptor function as a 'partial' negative modulator of desensitization that — unlike the related compound cyclothiazide — was essentially devoid of neurotoxicity at the concentrations tested (Impagnatiello 1997), an effect traceable to specific AMPA-receptor splice variants and Na+/Ca2+ currents (Longone 1998).
Broader reviews place IDRA-21 within the positive-AMPA-modulator ('ampakine') class, which is generally procognitive in animal models of memory (Black 2005). That preclinical signal is real and is why the level is 'Emerging' rather than dismissed — but it would be dishonest to present any of it as human evidence.
Memory and learning enhancement has been shown in rodents and a handful of monkey studies and is UNPROVEN in humans; nothing about dose, durability, tolerance or chronic safety in people can be inferred from it.
The principal safety concern is mechanistic: potentiating AMPA/glutamate transmission carries a theoretical EXCITOTOXICITY and SEIZURE risk, particularly with chronic dosing or high doses — the very preclinical papers that show IDRA-21's low acute neurotoxicity also flag that strong AMPA potentiators (e.g. cyclothiazide) can be frankly neurotoxic, so the margin is a property of dose and compound, not a free pass.
On top sits the grey-market reality: IDRA-21 is sold as an unregulated 'research chemical' / nootropic of unverified identity, purity and dose, frequently labelled 'not for human consumption', taken with no medical supervision and no monitoring for seizures or other harms, and with entirely uncharacterised drug interactions.
The evidence score is low precisely because the dominant signal is an ABSENCE of human data against a plausible mechanistic harm.
This is an informational, harm-reduction entry: the responsible conclusion is that IDRA-21 is a preclinically-promising but human-untested ampakine sold as a nootropic, not a supported intervention, and there is no human use this library endorses.
IDRA-21 binds an allosteric site on AMPA-subtype glutamate receptors and slows their rapid agonist-induced desensitization, so each glutamate pulse yields a larger, longer Na+/Ca2+ current. This facilitation of fast excitatory transmission is the ampakine mechanism that, in animals, underlies enhanced long-term potentiation and learning. Characterised in cultured neurons and rodents — its receptor pharmacology in humans is untested.
By amplifying AMPA-mediated transmission, IDRA-21 enhanced learning and memory tasks in rodents and non-human primates and was reported several-fold more potent than the prototype ampakine aniracetam. This is a mechanism demonstrated in animals and in vitro; it has NOT been shown to translate to human cognition, and any 'nootropic' benefit in people is an extrapolation, not a trial result.
Potentiating glutamate signalling is a double-edged mechanism: excessive AMPA-receptor activation can drive excitotoxic injury and lower seizure threshold. In vitro IDRA-21 appeared devoid of neurotoxicity at the concentrations tested while the stronger modulator cyclothiazide was overtly neurotoxic — so the safety margin is a property of dose and compound, not assured. This theoretical risk is wholly uncharacterised in humans, especially with chronic or high-dose grey-market use.
How IDRA-21 works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
There is no established or legitimate human dose. IDRA-21 is a grey-market 'research chemical' AMPAKINE with NO human clinical trials, no approval, and no pharmacovigilance — this library does NOT provide a dosing protocol. The only quantitative figures come from animal work: oral IDRA-21 at roughly 3-5.6 mg/kg reversed a learning deficit in patas monkeys (Thompson 1995) and racemic IDRA-21 enhanced rat water-maze performance — animal research doses that are NOT human recommendations and cannot be scaled to people. Vendor and forum figures are unverified extrapolations for a product of unknown identity and purity, taken without medical supervision or seizure monitoring.
Can be taken without food
| Form | Type |
|---|---|
| 💊No human form is endorsed — IDRA-21 is an unstudied-in-humans 'research chemical' ampakine with no approved or supplement form | Recommended |
There is no over-the-counter, supplement or prescription form of IDRA-21. Grey-market powder/capsules are of unverified identity and purity and are frequently sold 'not for human consumption'.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: No human timing is endorsed. IDRA-21 is a preclinically-studied AMPAKINE with no human trials and a theoretical excitotoxicity/seizure risk. Morning-only framing is harm-reduction for a CNS-active agent if exposure occurs; this library does not schedule its use.
Dose-response data unavailable. The current published research for IDRA-21 does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
There are no human clinical trials of IDRA-21 — none. No demonstrated cognitive, memory or performance benefit in people, and no human safety data. The entire evidence base is rodent and non-human-primate behavioural studies plus in-vitro electrophysiology. Any 'nootropic' benefit claimed for humans is extrapolated from animals, not measured.
As an AMPAKINE, IDRA-21 enhanced learning and memory in rats (water-maze performance) and reversed a drug-induced learning deficit in monkeys, where it was estimated ~10x more potent than aniracetam. This is a genuine preclinical signal — but it is animal/primate-only and UNPROVEN in humans; whether it translates, at what dose, with what durability or tolerance, and at what cost, is entirely unknown, which is why it is framed as a trade-off rather than a benefit.
The positive-AMPA-modulator class is generally procognitive in animal models of attention and memory, and IDRA-21 is marketed on that basis. But no human study has tested IDRA-21 for focus, attention or cognition, so any benefit is assumed, not shown, and may not transfer from rodents/monkeys to people at unknown grey-market doses.
Amplifying AMPA/glutamate transmission carries a mechanistic risk of excitotoxic neuronal injury and lowered seizure threshold, particularly with chronic or high-dose use. IDRA-21 looked non-neurotoxic in vitro at tested concentrations, but the related stronger modulator cyclothiazide was overtly neurotoxic — the margin depends on dose and is uncharacterised in humans, where it is taken with no seizure monitoring.
IDRA-21 is sold as an unregulated 'research chemical' of unverified identity, purity and dose, often labelled 'not for human consumption'. A buyer cannot confirm what the material is, how much is in it, or what contaminants it carries — there is no quality system and no medical oversight, so even the animal-study pharmacology cannot be assumed to apply.
Avoid — IDRA-21's benefit is shown only in rodents and monkeys and is UNPROVEN in humans, against a theoretical excitotoxicity/seizure risk and grey-market product of unverified identity and dose. There is no human evidence of benefit or safety.
Avoid — potentiating AMPA/glutamate transmission can theoretically provoke seizures, and IDRA-21 is taken with no monitoring.
Avoid — the excitotoxicity risk of enhanced glutamate signalling is uncharacterised and potentially harmful in vulnerable brains.
Avoid — additive seizure/excitotoxicity risk is uncharacterised and unmonitored.
Avoid entirely — there is no human or developmental safety data of any kind.
IDRA-21 potentiates excitatory AMPA/glutamate transmission, which can lower seizure threshold; combining it with drugs that also lower seizure threshold could additively raise seizure risk. This is uncharacterised in humans and entirely unmonitored.
Stacking IDRA-21 with other AMPA modulators or glutamatergic nootropics could compound excitatory drive and excitotoxicity/seizure risk in an unpredictable, dose-uncertain way for a grey-market product.
Tip: Mechanistic risk of potentiating AMPA/glutamate transmission, plausibly worse with high or chronic doses; uncharacterised in humans and taken with no seizure monitoring. Any seizure, convulsion or new neurological symptom after use is a medical emergency — seek urgent care.
Tip: Enhanced excitatory transmission can plausibly produce overstimulation, anxiety or headache. There is no human dose-finding to bound these effects for an analogue of uncertain potency; stop use if they occur.
Tip: Unverified 'research chemical' material may be mis-identified, contaminated or mis-dosed, so adverse effects may stem from impurities rather than IDRA-21 itself. There is no quality system to mitigate this — the only harm-reduction is not to ingest unverified material.
Tip: With no human data, the consequences of repeated or chronic dosing — tolerance, neuronal injury, withdrawal — are entirely unknown and cannot be monitored. Absence of reported harm reflects absence of study, not safety.
The commonly studied dose of IDRA-21 is There is no established or legitimate human dose. IDRA-21 is a grey-market 'research chemical' AMPAKINE with NO human clinical trials, no approval, and no pharmacovigilance — this library does NOT provide a dosing protocol. The only quantitative figures come from animal work: oral IDRA-21 at roughly 3-5.6 mg/kg reversed a learning deficit in patas monkeys (Thompson 1995) and racemic IDRA-21 enhanced rat water-maze performance — animal research doses that are NOT human recommendations and cannot be scaled to people. Vendor and forum figures are unverified extrapolations for a product of unknown identity and purity, taken without medical supervision or seizure monitoring.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take IDRA-21 is in the morning. It can be taken on an empty stomach. There is no human dosing protocol and no human use this library endorses; morning framing is harm-reduction only (a CNS-active cognition agent is least disruptive earlier in the day), and the compound is sandboxed from the stack timing optimizer.
IDRA-21 should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are seizure / excitotoxicity risk (theoretical, dose-dependent), CNS overstimulation (anxiety, agitation, headache), harms from grey-market identity / purity / dose. Use caution if any of these apply to you: Any human use — IDRA-21 is an UNSTUDIED-IN-HUMANS grey-market 'research chemical' with no human clinical trials, no approval, and product of unverified identity, purity and dose; it is NOT a dietary supplement and NOT an approved medicine; Anyone seeking it as a memory / cognition 'nootropic' — the benefit is shown only in rodents and monkeys and is UNPROVEN in humans, against a theoretical excitotoxicity/seizure risk; Anyone with epilepsy, a seizure history, or a lowered seizure threshold — potentiating AMPA/glutamate transmission can theoretically provoke seizures.
An atypical antidepressant — brand Stablon/Coaxil/Tatinol — approved and prescribed for major depression (and anxious depression) in parts of Europe, Asia and Latin America, where randomized trials show efficacy comparable to SSRIs and tricyclics, often with better tolerability at the therapeutic dose (12.5 mg three times daily). Mechanistically it is unusual: it modulates the stress system and enhances glutamatergic/hippocampal plasticity, and — the critical fact for harm reduction — it is a FULL MU-OPIOID RECEPTOR AGONIST. That opioid action explains both its antidepressant effect AND its abuse potential. In the United States it is NOT FDA-approved; the FDA has warned about it, and it is sold illicitly as an unapproved 'nootropic'/'supplement' ('Tianaa', 'Za Za', 'Pegasus') nicknamed 'gas station heroin'. The dominant recent US literature is not efficacy but ABUSE, DEPENDENCE, opioid-like WITHDRAWAL, overdose/toxicity (usually at supratherapeutic doses far above the clinical dose), and rising poison-center exposures. The honest framing: a genuine antidepressant abroad with proven short-term efficacy at the prescribed dose, but a mu-opioid agonist carrying real dependence/abuse/withdrawal/overdose risk and no US approval. Informational, harm-reduction entry only — not a recommendation, and not a substitute for clinician-supervised treatment.
Because IDRA-21 is sold as an unregulated 'research chemical', the substance, its purity, its actual dose and its contaminants are not assured. A buyer cannot know whether what they ingest matches any label or any of the animal-study doses, and there is no quality system, no medical monitoring and no characterisation of interactions or chronic effects.
Combining a glutamate-potentiating ampakine with stimulants or other CNS-active agents has no human safety data; additive overstimulation and lowered seizure threshold cannot be excluded for a compound of unknown potency.
An excitatory ampakine could theoretically oppose the action of antiepileptic drugs or interact unpredictably with sedatives; no interaction data exist, so any concurrent prescription is an unmonitored, uncharacterised risk.